Importantly, our discovery that USP22-FoxM1-integrin b1 pathway is critical for breast cancer self-renewal indicates that simultaneous USP22 and integrin b1 targeting may achieve a synergistic efficacy in combating human cancers, which leads to reduced therapeutic doses and side effects from both sides. Here, USP22 is linked to cancer.